Clinical Trial Update: Phase I Trial of Biweekly Gemcitabine & Paclitaxel & Low-Dose Radiation for Metastatic or Recurrent Head & Neck Cancer [Phase 1]

View source ↗

Summary

A Phase I trial evaluating biweekly gemcitabine and paclitaxel with low-dose radiation for metastatic or recurrent head and neck cancer has been terminated. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• Taxol (paclitaxel)

Snippet

Sponsor: Susanne Arnold | Conditions: Head and Neck Cancer | Phase 1 | Status: TERMINATED